The positive results in both safety profiles and clinical endpoints in these trials have resulted in the approval of voretigene neparvovec as the first FDA-approved gene therapy for patients with RPE65-associated retinopathy, which is now commercially available as Luxturna® [20,25,26,27]. This evidence concerns the gene RPE65 and retinal disorder.